Sacral Neuromodulation: Determining Predictors of Success.

[1]  S. Marinkovic,et al.  Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1–9 V) during Stage 1 sacral neuromodulation , 2018, BJU international.

[2]  D. Myers,et al.  Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. , 2018, European urology.

[3]  K. Matzel,et al.  International continence society best practice statement for use of sacral neuromodulation , 2018, Neurourology and urodynamics.

[4]  H. Goldman,et al.  Motor Response Matters: Optimizing Lead Placement Improves Sacral Neuromodulation Outcomes , 2017, The Journal of urology.

[5]  C. Comiter,et al.  Five‐Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation , 2018, The Journal of urology.

[6]  G. V. van Koeveringe,et al.  Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome? , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[7]  J. Gani,et al.  Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment , 2017, Neurourology and urodynamics.

[8]  M. Paraiso,et al.  Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls , 2017, The Journal of urology.

[9]  J. Boura,et al.  Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients , 2017, Neurourology and urodynamics.

[10]  D. Liberman,et al.  Sacral Neuromodulation in Urological Practice. , 2017, Urology.

[11]  J. Boura,et al.  Number of active electrodes at time of staged tined lead interstim implant does not impact clinical outcomes , 2016, Neurourology and urodynamics.

[12]  R. Dmochowski,et al.  The Burden of Overactive Bladder on US Public Health , 2016, Current Bladder Dysfunction Reports.

[13]  K. Peters,et al.  Proof of Concept Trial on Changes in Current Perception Threshold After Sacral Neuromodulation , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[14]  Stephanie A. Jacobs,et al.  Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet , 2014, Neurourology and urodynamics.

[15]  T. Marcelissen,et al.  Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. , 2013, The Journal of urology.

[16]  Claire C. Yang,et al.  Reoperation After Sacral Neuromodulation Therapy: A Single-Institution Experience , 2013, Female pelvic medicine & reconstructive surgery.

[17]  J. Boura,et al.  Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. , 2013, Urology.

[18]  Jennifer M Wu,et al.  Does Obesity Impact the Success of an InterStim Test Phase for the Treatment of Refractory Urge Urinary Incontinence in Female Patients? , 2012, Female pelvic medicine & reconstructive surgery.

[19]  E. Lukacz,et al.  Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. , 2012, The Journal of urology.

[20]  T. Yazdany,et al.  Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women , 2011, International Urogynecology Journal.

[21]  J. Gajewski,et al.  Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. , 2011, The Journal of urology.

[22]  B. Schurch,et al.  Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. , 2010, European urology.